Skip to content

Exablate

by Insightec

PMA P110039

Active United States

PMA

Valid until

No expiry

PMA approval is not time-limited

FDA recalls

None found

in data synced 6 Oct 2026

Documents

PMA P110039↗

FDA record

Trust

Unverified

Source FDA PMA, synced 6 Oct 2026.

Regulatory status

as of registry sync 6 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA PMAAPPR Approved NumberP110039 Date18 Oct 2012ApprovedStatusActive

Official records

From the FDA record

FDA PMA P110039

Received by the FDA
5 Dec 2011
FDA decision
18 Oct 2012
FDA review time
318 days from receipt to decision
Expedited review
Yes
Docket number
12M-1085
Approval order statement, verbatim
APPROVAL FOR THE EXABLATE SYSTEM, MODEL 2000/2100 /2100 VI. THIS DEVICE IS INDICATED FOR PAIN PALLIATION OF METASTATIC BONE CANCER IN PATIENTS 18 YEARS OF AGE OR OLDER WHO ARE SUFFERING FROM BONE PAIN DUE TO METASTATIC DISEASE AND WHO ARC FAILURES OF STANDARD RADIATION THERAPY, OR NOT CANDIDATES FOR, OR REFUSED RADIATION THERAPY. THE BONE TUMOR TO BE TREATED MUST BE VISIBLE ON NON-CONTRAST MR AND DEVICE ACCESSIBLE.

From the FDA PMA record P110039 (openFDA), as read on 6 Oct 2026. Quoted as published, gaps included; nothing on this list is generated.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA PMA Active

Specification

PMA

Generic name
Ablation system, high intensity focused ultrasound (HIFU), MR-guided
PMA number
FDA product code
NRZ
Device class
Class III
Advisory committee
General, Plastic Surgery
FDA decision
APPR Approved

Overview

AI-generated summary, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

The Exablate System is an MR-guided high intensity focused ultrasound (HIFU) ablation system designed for medical procedures. It is indicated for the pain palliation of metastatic bone cancer in patients 18 years of age or older who are suffering from bone pain due to metastatic disease.

This device is intended for patients who are failures of standard radiation therapy, or who are not candidates for or have refused radiation therapy. The bone tumor targeted for treatment must be visible on non-contrast MR and accessible by the device. The system is authorized under FDA PMA P110039.

Devices cleared under P110039

1 device · FDA GUDID

Devices that FDA's GUDID lists as cleared or approved under this submission number. One submission usually covers a whole product family, so the sizes and models are listed here once.

Devices cleared under P110039
UDI-DISize and differences
Patient accessory kit for Body
INSIGHTEC LTD
SET000016 / Patient accessory kit for Body07290015461047 —On the market

Other devices from Insightec